
European Commission Approves Zynyz for First-Line Treatment of Advanced Anal Cancer, Says Incyte
European Commission Approves Zynyz® (retifanlimab) as a First-Line Treatment for Patients with Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) Incyte has announced that the European Commission has granted approval for Zynyz (retifanlimab) to be used in combination with…












